Photo of Donna Mildvan

Donna Mildvan

Print ProfilePrint Profile


  • Infectious Disease

  • American Board of Internal Medicine


  • MD, Johns Hopkins School of Medicine

  • Internship, Flexible Intern
    Mount Sinai School of Medicine

  • Residency, Internal Medicine
    Mount Sinai School of Medicine

  • Fellowship, Infectious Disease
    Mount Sinai School of Medicine


    Donna Mildvan, M.D., Professor of Medicine, Icahn School of Medicine at Mount Sinai; formerly Professor of Medicine, Albert Einstein College of Medicine; Co-Principal Investigator/Principal Investigator, AIDS Clinical Trials Group (1987-2008); Chief, Infectious Diseases and AIDS Divisions and Director of AIDS Research at Mount Sinai Beth Israel (formerly Beth Israel Medical Center).

     Responsible for early descriptions of AIDS and complications of HIV infection, including the lymphadenopathy syndrome, and collaborations demonstrating LAV (HIV) in the first US AIDS cases and the first convincing evidence that the brain harbored and could transmit HIV.

    Focus has been on antiretroviral drug development, innovation in biomarker research and study design, championing ways to improve diversity in clinical trials participation, and optimizing management of community acquired pneumonia.

    Led the ACTG’s trial A5073 on directly observed antiretroviral therapy, co-chaired the Surrogate Markers Collaborative Group, has been site PI for the NIAID-sponsored “Addressing Health Disparities in AIDS Clinical Trials, Project ACT.”

    Chair of numerous study protocols, and member of numerous NIH review committees, including the NIAID AIDS Charter Review Committee.
    Consultant to the FDA, CDC.

    Developed an algorithm for HIV biomarker validation which has achieved broad recognition and applicability in disciplines outside the field of HIV.
    Chaired and reconfigured the ACTG’s Underrepresented Populations Committee (2002-2008) to concentrate on increasing minority access to clinical trials.

    Longstanding interest in community acquired pneumonia, membership on the national Pneumonia Technical Expert Panel since 2010, design of and participation in multisite studies aimed at new drug development for CAP, as well as contributions to single site studies addressing antimicrobial prescribing and its impact on the emergence of drug resistance.  


Directs Clinical Trials Research Unit in Infectious Diseases and AIDS at Mount Sinai Beth Israel with focus including treatment strategies for HIV infection, HIV and hepatitis co-infection, community acquired pneumonia, C difficile infection, and antimicrobial therapy management.


Phillips SC, Mildvan D, William DC, Gelb A, White MD. Sexual transmission of enteric protozoa and helminths in a venereal disease clinic population. N Engl J Med. 1981; 305:603-6..;.


Mildvan D, Mathur U, Enlow RW, Romain PL, Winchester RJ, Colp C, Singman H, Adelsberg BR, Spigland I. Opportunistic infections and immune deficiency in homosexual men. Annals of internal medicine 1982 Jun; 96(6 Pt 1).

Gajdusek DC, Amyx HL, Gibbs CJ, Asher DM, Yanagihara RT, Rodgers-Johnson P, Brown PW, Sarin PS, Gallo RC, Maluish A. Transmission experiments with human T-lymphotropic retroviruses and human AIDS tissue. Lancet 1984 Jun; 1(8391).

Curran JW, Lawrence DN, Jaffe H, Kaplan JE, Zyla LD, Chamberland M, Weinstein R, Lui KJ, Schonberger LB, Spira TJ. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. The New England journal of medicine 1984 Jan; 310(2).

Barré-Sinoussi F, Mathur-Wagh U, Rey F, Brun-Vezinet F, Yancovitz SR, Rouzioux C, Montagnier L, Mildvan D, Chermann JC. Isolation of lymphadenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS. JAMA; 253(12).

Mathur-Wagh U, Mildvan D, Spigland I, Brun-Vezinet F, Barre-Sinoussi F, Montagnier L, Chermann JC. Longitudinal assessment of persistent generalized lymphadenopathy (PGL) in homosexual men. Advances in experimental medicine and biology 1985; 187.

Des Jarlais DC, Friedman SR, Sotheran JL, Wenston J, Marmor M, Yancovitz SR, Frank B, Beatrice S, Mildvan D. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA 1994 Jan; 271(2).

Stekol'nikov LI, Litvinova TP, Ignat'eva NS, Sintsova MA, Anderson AA. [Chemical composition and standardization of the preparation . Farmat͡sii͡a; 25(6).

Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. The Journal of infectious diseases 2004 May; 189(10).

Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997 May; 24(5).

Mildvan D, Bassiakos Y, Zucker ML, Hyslop N, Krown SE, Sacks HS, Zachary J, Paredes J, Fessel WJ, Rhame F, Kramer F, Fischl MA, Poiesz B, Wood K, Ruprecht RM, Kim J, Grossberg SE, Kasdan P, Bergé P, Marshak A, Pettinelli C. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068. Antiviral therapy 1996 Apr; 1(2).

Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Lindsay RJ, Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins GK, Altfeld M. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nature medicine 2009 Aug; 15(8).

Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005 Mar; 40(6).

Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. The Journal of infectious diseases 2004 May; 189(10).

Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Archives of internal medicine 2009 Jul; 169(13).

Ruhe JJ, Kreiswirth B, Perlman DC, Mildvan D, Koll B. Impact of results of methicillin-resistant Staphylococcus aureus surveillance culture of nasal specimens on subsequent antibiotic prescribing patterns. Infection control and hospital epidemiology 2010 Aug; 31(8).

Slim J, Mildvan D, Han J, Korner E. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV. Journal of the International Association of Providers of AIDS Care; 12(5).

Raveendran R, Adithan C, Sriram G, Krishnan M, Bapna JS. Ampicillin pharmacokinetics in Indian geriatric subjects. Indian journal of medical sciences 1990 Mar; 44(3).

Ruhe J, Mildvan D. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?. Infectious disease clinics of North America 2013 Mar; 27(1).

Gwadz MV, Leonard NR, Cleland CM, Riedel M, Banfield A, Mildvan D. The effect of peer-driven intervention on rates of screening for AIDS clinical trials among African Americans and Hispanics. American journal of public health 2011 Jun; 101(6).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Mildvan during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Scientific Advisory Board:

  • Cempra Pharmaceuticals; Janssen Scientific Affairs, LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


350 East 17th St.
New York, NY 10003

Tel: 212-420-4005
Fax: 212-420-4498


Residential Tower
10 East 102nd Street
New York, NY 10029